title: Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system.
abstract: Angiotensin-converting enzyme (ACE) inhibition alone or in combination with the angiotensin type-I receptor (AT1) antagonist losartan augments circulating levels of the bioactive peptide angiotensin-(1-7) [Ang-(1-7)]. Hence, we determined whether Ang-(1-7) contributes to the hypotensive effects produced by the combined administration of lisinopril and losartan in spontaneously hypertensive rats by blocking the peptide's synthesis with either of two structurally different neprilysin inhibitors. Intravenous administration of CGS 24592 (30 mg/kg) to rats in which blood pressure was normalized by 9 days of therapy with lisinopril and losartan elicited an elevation of mean arterial pressure that was sustained throughout the infusion period and for 20 minutes thereafter. The hypertensive response was associated with a 62% reduction in circulating levels of Ang-(1-7) and no change in plasma angiotensin II (Ang II). Intravenous infusion of one other neprilysin inhibitor (SCH 39370, 30 mg/kg) produced an increase in mean blood pressure of a magnitude similar to that found with CGS 24592. Pretreatment with the nonselective antagonist [Sar1,Thr8]-Ang II abolished any additional pressor effects of either neprilysin inhibitor in spontaneously hypertensive rats treated with lisinopril or losartan. However, neither the endothelin A antagonist BQ123 nor the kinin B2 antagonist HOE 140 had an effect on basal blood pressure or altered the pressor or heart rate effects of the neprilysin inhibitors. These data suggest that inhibition of Ang-(1-7) formation in rats exposed to the combined blockade of Ang II production and activity is associated with a reversal of the antihypertensive actions produced by these therapies. Thus, endogenous Ang-(1-7) functions as a vasodilator hormone in this form of genetic hypertension.
authors.affiliation: Hypertension Center, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157-1095, USA.
authors.forename: S N
authors.initials: SN
authors.lastname: Iyer
authors.forename: C M
authors.initials: CM
authors.lastname: Ferrario
authors.forename: M C
authors.initials: MC
authors.lastname: Chappell
mesh_terms: D000803:Angiotensin I; D000804:Angiotensin II / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000503:physiopathology*; D007700:Kinetics; D017706:Lisinopril / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D015260:Neprilysin / Q000037:antagonists & inhibitors; D063065:Organophosphonates / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; C086164:CGS 24592; D004151:Dipeptides; D063065:Organophosphonates; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D011480:Protease Inhibitors; D000804:Angiotensin II; C060631:Sch 39370; D010649:Phenylalanine; C014805:angiotensin II, Sar(1)-Thr(8)-; C065679:icatibant; D000803:Angiotensin I; D017706:Lisinopril; D015260:Neprilysin; C118790:angiotensin I (1-7); D019808:Losartan; C072247:cyclo(Trp-Asp-Pro-Val-Leu); D001920:Bradykinin